Quick Answer
Compass Therapeutics, Inc. reported Net Income Loss of -$66.49 million for the year ending 2025.
- Compass Therapeutics, Inc. showed a decrease of -34.7% in Net Income Loss from 2024 to 2025.
- This data is from Compass Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$8.5 thousand | Q3 2018: -$8.6 thousand | Q4 2018: -$10.1 thousand | Q1 2019: -$10.77 million | Q2 2019: -$8.81 million | Q3 2019: -$8.55 million | Q4 2019: -$11.7 thousand | Q1 2020: -$6.40 million | Q2 2020: -$5.56 million | Q3 2020: -$9.15 million | Q1 2021: -$7.42 million | Q2 2021: -$55.80 million | Q3 2021: -$5.98 million | Q1 2022: -$7.16 million | Q2 2022: -$8.49 million | Q3 2022: -$11.98 million | Q1 2023: -$7.84 million | Q2 2023: -$11.28 million | Q3 2023: -$9.96 million | Q1 2024: -$10.79 million | Q2 2024: -$13.08 million | Q3 2024: -$10.48 million | Q1 2025: -$16.63 million | Q2 2025: -$19.88 million | Q3 2025: -$14.26 million.
- Over the full 10 years of available data (2018 to 2025), Compass Therapeutics, Inc.'s Net Income Loss has declined by 189,586.8%.
- Historical annual values: Fiscal year 2025: -$66.49 million | Fiscal year 2024: -$49.38 million | Fiscal year 2023: -$42.49 million | Fiscal year 2022: -$39.23 million | Fiscal year 2021: -$82.18 million | Fiscal year 2020: -$29.50 million | Fiscal year 2020: -$37.5 thousand | Fiscal year 2019: -$34.74 million | Fiscal year 2019: -$36.0 thousand | Fiscal year 2018: -$35.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: